結節性癢疹（PN）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 德國結節性癢疹市場預計將從2025年的4,500萬美元成長到2035年的9,500萬美元。
• 推動市場成長的因素如下：
• 標靶生物製藥的應用日益廣泛
• 診斷技術的進步與對疾病認知的提高
• 未來的成長取決於能夠實現持續症狀控制和改善患者預後的治療方法。

結節性癢疹（PN）概述

結節性癢疹（PN）是一種慢性、劇烈搔癢的皮膚病，由反覆抓癢引起的惡性循環所致。它會導致皮膚上出現堅硬、持續的結節，嚴重影響睡眠和日常生活。多年來，治療選擇僅限於仿單標示外局部藥物、照光治療以及各種神經調節劑和免疫抑制劑，但這些藥物通常只能部分緩解症狀。這反映了長期以來人們對該疾病潛在生物學機制缺乏了解。然而，隨著人們逐漸認知到該疾病源於免疫系統和神經系統之間的特定相互作用，情況發生了變化。這為標靶生物療法鋪平了道路，目前已有兩種標靶生物製藥療法獲得批准。這些療法在搔癢路徑的不同階段阻斷搔癢：一種作用於更廣泛的上游發炎訊號，而另一種則更直接地靶向神經特異性的搔癢介導物質。由於這兩種療法在緩解搔癢的速度和可見結節隨時間消失的程度上存在顯著差異，因此在選擇治療方案時，考慮哪些症狀對每位患者最為重要變得越來越重要。

主要亮點

• 根據預測，德國結節性癢疹（PN）患者人數將從2025年的127,122 人增加到2035年的129,438 人。
• 結節性癢疹是一種慢性發炎性皮膚病，其特徵是劇烈搔癢和結節性皮膚損傷。
• 這種疾病的特徵是持續性搔癢和反覆發作，嚴重影響患者的生活品質。
• 目前仍有大量未被滿足的需求，即需要提供持續止癢和長期疾病管理的治療方法。

形式和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

提及公司

• Trevi Therapeutics
• Incyte Corporation
• Sanofi
• Amgen
• Beijing InnoCare Pharma Tech Co., Ltd.
• Guangdong Hengrui Pharmaceutical Co., Ltd.
• Genentech, Inc.

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者群體
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法 - 概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章 未滿足的需求與TPP分析

• 主要未滿足需求及新興療法的未來成就
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Prurigo Nodularis (PN) Market Outlook

Thelansis's "Prurigo Nodularis (PN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prurigo Nodularis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Prurigo Nodularis (PN) Overview

Prurigo nodularis is a chronic, intensely itchy skin condition driven by a self-perpetuating cycle of itching and scratching that produces hardened, persistent nodules across the skin and carries a significant burden on sleep and daily quality of life. For years, treatment options were limited to off-label use of topical agents, phototherapy, and various neuromodulating or immunosuppressive medications that often provided incomplete relief, reflecting how poorly understood the underlying biology was for a long time. That changed with growing recognition that the disease stems from a specific interaction between the immune system and the nervous system, which paved the way for targeted biologic therapies, with two now approved that interrupt this itch-driving pathway at different points, one addressing a broader upstream inflammatory signal and the other targeting a nerve-specific itch mediator more directly. Because these two options differ meaningfully in how quickly they relieve itch versus how fully they clear visible nodules over time, treatment selection increasingly considers which symptom matters most to an individual patient.

Key Highlights

• In Germany, the prevalent Prurigo Nodularis (PN) population is projected to increase from 127,122 in 2025 to 129,438 by 2035.
• Prurigo Nodularis is a chronic inflammatory skin disease characterized by severe pruritus and nodular skin lesions.
• Persistent itching and recurrent disease significantly impair patients' quality of life.
• Significant unmet need remains for therapies that provide sustained itch relief and long-term disease control.

Market Overview

• The Germany Prurigo Nodularis market is projected to grow from $45M in 2025 to $95M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted biologic therapies
• Improved diagnosis and growing disease awareness
• Future growth will depend on therapies capable of delivering durable symptom control and improved patient outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Trevi Therapeutics
• Incyte Corporation
• Sanofi
• Amgen
• Beijing InnoCare Pharma Tech Co., Ltd.
• Guangdong Hengrui Pharmaceutical Co., Ltd.
• Genentech, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)